Converging Evidence of NMDA Receptor Hypofunction in the Pathophysiology of Schizophrenia (Q22241679)

Europe PubMed Central

title

Converging Evidence of NMDA Receptor Hypofunction in the Pathophysiology of Schizophrenia (English)

0 references

0 references

1 reference

JOSEPH T. COYLE

1

Joseph T

Coyle

1 reference

PubMed

8 February 2023

GUOCHUAN TSAI

series ordinal

2

author given names

Guochuan

author last names

Tsai

1 reference

PubMed

8 February 2023

DONALD GOFF

series ordinal

3

author given names

Donald

author last names

Goff

1 reference

PubMed

8 February 2023

language of work or name

English

0 references

publication date

November 2003

0 references

number of pages

10

1 reference

Annals of the New York Academy of Sciences

inferred from page(s)

published in

1 reference

Recent advances in the phencyclidine model of schizophrenia

volume

1003

0 references

issue

1

0 references

page(s)

318-327

0 references

cites work

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

Abnormal excitatory neurotransmitter metabolism in schizophrenic brains

21 January 2018

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

7 January 2021

Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

7 January 2021

Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

7 January 2021

Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

7 January 2021

Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia.

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

7 January 2021

Progressive decrease of left Heschl gyrus and planum temporale gray matter volume in first-episode schizophrenia: a longitudinal magnetic resonance imaging study

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

7 January 2021

Metabotropic glutamate receptor 3 (GRM3) gene variation is not associated with schizophrenia or bipolar affective disorder in the German population

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

7 January 2021

Comparative genome- and proteome analysis of cerebral cortex from MK-801-treated rats

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

7 January 2021

Glutamate carboxypeptidase II is expressed by astrocytes in the adult rat nervous system

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

7 January 2021

Age-specific neurotoxicity in the rat associated with NMDA receptor blockade: potential relevance to schizophrenia?

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

7 January 2021

Up-regulation of GABAA receptor binding on neurons of the prefrontal cortex in schizophrenic subjects

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

7 January 2021

Increased cortical kynurenate content in schizophrenia

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

7 January 2021

Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

7 January 2021

A.E. Bennett Research Award. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

7 January 2021

D-serine added to antipsychotics for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

7 January 2021

Schizophrenia: genes and environment

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

7 January 2021

Subunit specificity and mechanism of action of NMDA partial agonist D-cycloserine

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

7 January 2021

Genes for schizophrenia? Recent findings and their pathophysiological implications

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

7 January 2021

Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

7 January 2021

Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

7 January 2021

Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG).

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

7 January 2021

Linking Hebb's coincidence-detection to memory formation

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

7 January 2021

Neuregulin and ErbB receptor signaling pathways in the nervous system

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

7 January 2021

Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

7 January 2021

Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

7 January 2021

Modulation of N-methyl-D-aspartate receptor function by glycine transport

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

7 January 2021

D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

7 January 2021

Direct calcium binding results in activation of brain serine racemase

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

7 January 2021

Neuregulin 1 and susceptibility to schizophrenia

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

7 January 2021

Reciprocal alterations in pre- and postsynaptic inhibitory markers at chandelier cell inputs to pyramidal neurons in schizophrenia

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

7 January 2021

Glycine tranporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

7 January 2021

Glycine uptake governs glycine site occupancy at NMDA receptors of excitatory synapses

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

7 January 2021

beta-NAAG rescues LTP from blockade by NAAG in rat dentate gyrus via the type 3 metabotropic glutamate receptor

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

7 January 2021

Dopamine receptors, neuroleptics, and schizophrenia

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

7 January 2021

Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

7 January 2021

GABA transporter-1 mRNA in the prefrontal cortex in schizophrenia: decreased expression in a subset of neurons

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

7 January 2021

The emerging role of glutamate in the pathophysiology and treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

7 January 2021

Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

7 January 2021

Effects of ketamine on leading saccades during smooth-pursuit eye movements may implicate cerebellar dysfunction in schizophrenia

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

7 January 2021

Effect of Phencyclidine in Chronic Schizophrenics

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

7 January 2021

Treatment-resistant schizophrenia--the role of clozapine

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

7 January 2021

NMDA-dependent modulation of CA1 local circuit inhibition.

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

7 January 2021

Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

7 January 2021

NMDA receptor antagonists disinhibit rat posterior cingulate and retrosplenial cortices: a potential mechanism of neurotoxicity.

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

7 January 2021

Ionotropic glutamate receptors as therapeutic targets in schizophrenia

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

7 January 2021

The Glutamatergic Dysfunction Hypothesis for Schizophrenia

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1300.020

7 January 2021

Identifiers

DOI

10.1196/ANNALS.1300.020

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017